Licensing Board Referral Report

Ashley Parsons, MPH
PDMP Program Manager

September 17, 2019
Purpose

• **Act 191 of 2016**

  (vi) Establish professionally developed criteria, with the advice of the advisory group, that generates referrals of prescription monitoring information to the appropriate licensing board in the Department of State. A referral may only be generated when the system produces an alert that there is a pattern of irregular data for a dispenser or prescriber which appears to deviate from the clinical standard.

• **Intent**

  To create a tool that considers current prescribing trends and alerts when there is a deviation

  Provide investigators with multiple data points and a uniform way to sort data, based on investigation needs
Planning Process

Plan

• Met internally to determine scope and intent of statute
• Identified preliminary metrics
• Presented preliminary metrics to Office of the Attorney General and the Department of State

Implement

• Finalized report
• Update and disseminate quarterly
• Utilized in DOS/OAG investigations
Metrics

Not Scored
  o Prescription count
  o Count of buprenorphine prescriptions

Scored
  o PDMP Registration status
  o Total MME
  o Average daily MME
  o Multiple provider episodes
  o Dangerous drug combinations
  o Rate of private pay
Rank score, based on:

- Registration
  - No = 1
- Standard deviation from the mean (1-3) for:
  - Total MMEs
  - Average MMEs
  - Multiple Provider Episodes
  - Dangerous Drug Combination
  - Private Pay
- Metrics can only add to the individual’s score, cannot subtract
- Metrics may be weighted
Feedback

- Timeliness of data
- Opportunity for increased collaboration
- Positive feedback from Department of State and Office of the Attorney General
- DOS investigative process
<table>
<thead>
<tr>
<th>NPI Classification</th>
<th>Count of Opioid Prescriptions</th>
<th>Count of Buprenorphine Prescriptions</th>
<th>Total MME</th>
<th>Average MME</th>
<th>Count of Patients with Multiple Provider Episodes</th>
<th>Count of Dangerous Drug Combinations</th>
<th>Rate of Private Payment Method (Cash, Credit Card, etc.) for Prescriptions</th>
<th>Registered With PDMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nurse Practitioner</td>
<td>522</td>
<td>0</td>
<td>1424404.5</td>
<td>122.5461805</td>
<td>15</td>
<td>259</td>
<td>0.024221453</td>
<td>Yes</td>
</tr>
<tr>
<td>Family Medicine</td>
<td>1089</td>
<td>0</td>
<td>4180273</td>
<td>135.2672243</td>
<td>1</td>
<td>330</td>
<td>0.213787761</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NPI Classification</th>
<th>Total MME Score</th>
<th>Average MME Score</th>
<th>Average MMEs Weighted Score</th>
<th>Count of Patients with Multiple Provider Episodes Score</th>
<th>Count of Dangerous Drug Combinations Score</th>
<th>Rate of Private Payment Method for Prescriptions Score</th>
<th>Combined Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nurse Practitioner</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>Family Medicine</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>
Future Implications

• Expand to all controlled substances
• Utilize for Academic Detailing
• Utilize for continuing medical education efforts
• Adopt additional metrics
• Collaboration with border states
Considerations & Lessons Learned

Components:

- Relationships with licensing entity and law enforcement
- Authority
- Defining appropriate metrics
- Automation of report and staffing considerations
Ashley Parsons, MPH
PDMP Program Manager
c-parsons@pa.gov

Jared Shinabery, MPH
PDMP Program Director
jshinabery@pa.gov